CSE Bulletin: Consolidation - NeonMind Biosciences Inc.

CSE Bulletin: Consolidation - NeonMind Biosciences Inc.

NeonMind Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every four (4) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 32,144,140 common shares.

The name and symbol will not change.

Please note that all open orders will be cancelled at the close of business on April 14, 2022. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

NeonMind Biosciences Inc. a annoncé une consolidation de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-consolidée pour quatre (4) actions ordinaires pré-consolidées.

En conséquence, les actions en circulation de la société seront réduites à environ 32 144 140 actions ordinaires.

Le nom et le symbole ne changeront pas.

Veuillez noter que tous les ordres ouverts seront annulés à la fermeture des bureaux le 14 avril 2022. Il est rappelé aux concessionnaires de saisir à nouveau leurs ordres en tenant compte du regroupement d'actions.

Trading on a Consolidated Basis/Négociation sur une base consolidée:

le 18 avril/April 2022

Record Date/Date d'enregistrement:

le 19 avril/April 2022

Symbol/Symbole:

NEON

NEW/NOUVEAU CUSIP:

64051V 30 3

NEW/NOUVEAU ISIN:

CA 64051V 30 3 9

Old/Vieux CUSIP & ISIN:

64051V105/CA64051V1058

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

NEON:CC
The Conversation (0)
NeonMind Biosciences

NeonMind Biosciences

Using Psychedelics as Treatment for Mental Health Disorders and Weight Management

Using Psychedelics as Treatment for Mental Health Disorders and Weight Management Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms in the center are surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain

On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as an alternative... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...

Interactive Chart

Latest Press Releases

Related News